EARS Auris Medical Holding AG gains 18% Jan 6, 2022

Auris Medical Holding Ltd., a development-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; and AM-201, which is in Phase 1b clinical trial for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.http://www.priceseries.com/trade/EARS-Auris-Medical-Holding-AG-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2021122720220106.html